Exploring the link between MORF4L1 and risk of breast cancer

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Martrat, Griselda ^a,b   Maxwell, Christopher A ^a,b   Tominaga, Emiko ^c   Porta de la Riva, Montserrat ^b   Bonifaci, Núria ^b   Gómez Baldó, Laia ^a,b   Bogliolo, Massimo ^d   Lázaro, Conxi ^b   Blanco, Ignacio ^b   Brunet, Joan ^e   Aguilar, Helena ^a   Fernández Rodríguez, Juana ^b   Seal, Sheila ^f   Renwick, Anthony ^f   Rahman, Nazneen ^f   Kühl, Julia ^g   Neveling, Kornelia ^g   Schindler, Detlev ^g   Ramírez, María J ^d   Castellà, María ^d   Hernández, Gonzalo ^d   Easton, Douglas F ^h   Peock, Susan ^h   Cook, Margaret ^h   Oliver, Clare T ^h   Frost, Debra ^h   Platte, Radka ^h   Evans, D Gareth ⁱ   Lalloo, Fiona ⁱ   Eeles, Rosalind ^j   Izatt, Louise ^k   Chu, Carol ^l   Davidson, Rosemarie ^m   Ong, Kai Ren ⁿ   Cook, Jackie ^o   Douglas, Fiona ^p   Hodgson, Shirley ^q   Brewer, Carole ^r   Morrison, Patrick J ^s   Porteous, Mary ^t   Peterlongo, Paolo ^u,v   Manoukian, Siranoush ^w   Peissel, Bernard ^w   Zaffaroni, Daniela ^w   Roversi, Gaia ^w   Barile, Monica ^x   Viel, Alessandra ^y   Pasini, Barbara ^z   Ottini, Laura ^aa   Putignano, Anna L ^ab,ac   Savarese, Antonella ^ad   Bernard, Loris ^x   Radice, Paolo ^u,v   Healey, Sue ^ae   Spurdle, Amanda ^ae   Chen, Xiaoqing ^ae   Beesley, Jonathan ^ae   Rookus, Matti A ^af   Verhoef, Senno ^af   Tilanus Linthorst, Madeleine A ^ag   Vreeswijk, Maaike P ^ah   Asperen, Christi J ^ah   Bodmer, Danielle ^ai   Ausems, Margreet G E M ^aj   van Os, Theo A ^ak   Blok, Marinus J ^al   Meijers Heijboer, Hanne E J ^am   Hogervorst, Frans B L ^af   Goldgar, David E ^an   Buys, Saundra ^ao   John, Esther M ^ap   Miron, Alexander ^aq   Southey, Melissa ^ar   Daly, Mary B ^as   Harbst, Katja ^at   Borg, Åke ^at   Rantala, Johanna ^au   Barbany Bustinza, Gisela ^au   Ehrencrona, Hans ^av   Stenmark Askmalm, Marie ^aw   Kaufman, Bella ^ax   Laitman, Yael ^ax   Milgrom, Roni ^ax   Friedman, Eitan ^ax,ay   Domchek, Susan M ^az   Nathanson, Katherine L ^az   Rebbeck, Timothy R ^az   Johannsson, Oskar T ^ba,bb   Couch, Fergus J ^aw,bc   Wang, Xianshu ^bc   Fredericksen, Zachary ^bc   Cuadras, Daniel ^b   Moreno, Víctor ^b   Pientka, Friederike K ^bd   Depping, Reinhard ^bd   Caldés, Trinidad ^be   Osorio, Ana ^bf   Benítez, Javier ^bf   Bueren, Juan ^bg   Heikkinen, Tuomas ^bh   Nevanlinna, Heli ^bh   Hamann, Ute ^bi   Torres, Diana ^bj   Caligo, Maria A ^bk   Godwin, Andrew K ^bl   Imyanitov, Evgeny N ^bm   Janavicius, Ramunas ^bn   Sinilnikova, Olga M ^bo,bp   Stoppa Lyonnet, Dominique ^bq,br,bs   Mazoyer, Sylvie ^bp   Verny Pierre, Carole ^bp   Castera, Laurent ^bq   De Pauw, Antoine ^bq   Bignon, Yves Jean ^bt   Uhrhammer, Nancy ^bt   Peyrat, Jean Philippe ^bu   Vennin, Philippe ^bu   Ferrer, Sandra F ^bv   Collonge Rame, Marie Agnès ^bw   Mortemousque, Isabelle ^bx   McGuffog, Lesley ^h   Chenevix Trench, Georgia ^ae   Pereira Smith, Olivia M ^c   Antoniou, Antonis C ^h   Cerón, Julián ^b   Tominaga, Kaoru ^c   Surrallés, Jordi ^d   Pujana, Miguel A ^a,b   more..

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c University of Texas Health Science Center   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k GUY S HOSPITAL   (United Kingdom)

^l ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^m NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

ⁿ BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^o SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^p NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q ST GEORGE S HOSPITAL   (United Kingdom)

^r ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^s BELFAST CITY HOSPITAL   (United Kingdom)

^t WESTERN GENERAL HOSPITAL   (United Kingdom)

^u NATIONAL CANCER INSTITUTE   (Italy)

^v FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^w IRCCS   (Italy)

^x EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^y CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^z UNIVERSITY OF TURIN   (Italy)

^aa SAPIENZA UNIVERSITY OF ROME   (Italy)

^ab UNIVERSITY OF FLORENCE   (Italy)

^ac Fiorgen Foundation for Pharmacogenomics   (Italy)

^ad REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^ae QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^af NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ag ERASMUS MEDICAL CENTER   (Netherlands)

^ah LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ai RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^aj UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ak ACADEMIC MEDICAL CENTER   (Netherlands)

^al MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^am VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^an UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^ao UNIVERSITY OF UTAH   (United States)

^ap CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^aq HARVARD MEDICAL SCHOOL   (United States)

^ar UNIVERSITY OF MELBOURNE   (Australia)

^as FOX CHASE CANCER CENTER   (United States)

^at LUND UNIVERSITY   (Sweden)

^au KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^av UPPSALA UNIVERSITY   (Sweden)

^aw LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^ax SHEBA MEDICAL CENTER   (Israel)

^ay TEL AVIV UNIVERSITY   (Israel)

^az UNIVERSITY OF PENNSYLVANIA   (United States)

^ba University of Pennsylvania School of Medicine ^*  (Iceland)

^bb UNIVERSITY OF ICELAND   (Iceland)

^bc MAYO CLINIC   (United States)

^bd UNIVERSITY OF LÜBECK   (Germany)

^be HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^bf Structural Biology and Biocomputing Programme   (Spain)

^bg CIEMAT   (Spain)

^bh HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^bi GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^bj PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^bk UNIVERSITY HOSPITAL OF PISA   (Italy)

^bl UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^bm N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^bn VILNIUS UNIVERSITY   (Lithuania)

^bo HOSPICES CIVILS DE LYON   (France)

^bp UNIVERSITÉ LYON 1   (France)

^bq INSTITUT CURIE   (France)

^br INSTITUT CURIE   (France)

^bs UNIVERSITÉ PARIS DESCARTES   (France)

^bt UNIVERSITÉ CLERMONT AUVERGNE   (France)

^bu CENTRE OSCAR LAMBRET   (France)

^bv CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^bw UNIVERSITY HOSPITAL OF BESANÇON   (France)

^bx CHU BRETONNEAU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MRG 15 PROTEIN; UNCLASSIFIED DRUG; FANCD2 PROTEIN, HUMAN; FANCONI ANEMIA GROUP D2 PROTEIN; MORF4L1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; RAD51 PROTEIN; REPLICATION FACTOR A; RPA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CAENORHABDITIS ELEGANS; CANCER RISK; CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; FAMILIAL CANCER; FANCONI ANEMIA; FIBROBLAST; GAMMA RADIATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; IMMUNOASSAY; IMMUNOPRECIPITATION; MORF4L1 GENE; MOUSE; NONHUMAN; ORTHOLOGY; PROTEIN INTERACTION; ANIMAL; BREAST TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MUTATION; RISK FACTOR; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; TWO HYBRID SYSTEM;

ANIMALS; BREAST NEOPLASMS; CAENORHABDITIS ELEGANS; CELL LINE; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MUTATION; NUCLEAR PROTEINS; RAD51 RECOMBINASE; REPLICATION PROTEIN A; RISK FACTORS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84860405722     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2862     Document Type: Article

References (69)

1. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
2. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919. 10.1056/NEJMra0809889, 3069698, 20484397.
3. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010, 42:410-414. 10.1038/ng.569, 20400964.
4. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010, 42:406-409. 10.1038/ng.570, 20400963.
5. Crossan GP, van der Weyden L, Rosado IV, Langevin F, Gaillard PH, McIntyre RE, Gallagher F, Kettunen MI, Lewis DY, Brindle K, Arends MJ, Adams DJ, Patel KJ. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet 2011, 43:147-152. 10.1038/ng.752, 21240276.
6. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011, 43:142-146. 10.1038/ng.750, 21240275.
7. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609. 10.1126/science.1073834, 12065746.
8. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
9. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, Ott J, Petrini J, Schindler D, Hanenberg H, Auerbach AD. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005, 37:931-933. 10.1038/ng1624, 16116424.
10. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, De Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005, 37:934-935. 10.1038/ng1625, 16116423.
11. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005, 8:255-265. 10.1016/j.ccr.2005.08.004, 16153896.
12. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622.
13. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319. 10.1038/nature05609, 17287723.
14. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668.
15. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164. 10.1038/ng1947, 17200671.
16. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, et al. Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO) RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007, 81:1186-1200. 10.1086/522611, 2276351, 17999359, Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO).
17. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275. 10.1016/S0092-8674(00)81847-4, 9008167.
18. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997, 386:804-810. 10.1038/386804a0, 9126738.
19. Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene 2007, 26:7720-7730. 10.1038/sj.onc.1210870, 18066084.
20. Alpi AF, Patel KJ. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amst) 2009, 8:430-435.
21. Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J, Andreassen PR. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J Cell Sci 2010, 123:1124-1130. 10.1242/jcs.060178, 2844321, 20332121.
22. Sy SM, Huen MS, Chen J. MRG15 is a novel PALB2 interacting factor involved in homologous recombination. J Biol Chem 2009, 284:21127-21131. 10.1074/jbc.C109.023937, 2755835, 19553677.
23. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, Assmann V, Elshamy WM, Rual JF, Levine D, Rozek LS, Gelman RS, Gunsalus KC, Greenberg RA, Sobhian B, Bertin N, Venkatesan K, Ayivi-Guedehoussou N, Sole X, Hernandez P, Lazaro C, Nathanson KL, Weber BL, Cusick ME, Hill DE, Offit K, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007, 39:1338-1349. 10.1038/ng.2007.2, 17922014.
24. Boxem M, Maliga Z, Klitgord N, Li N, Lemmens I, Mana M, de Lichtervelde L, Mul JD, van de Peut D, Devos M, Simonis N, Yildirim MA, Cokol M, Kao HL, de Smet AS, Wang H, Schlaitz AL, Hao T, Milstein S, Fan C, Tipsword M, Drew K, Galli M, Rhrissorrakrai K, Drechsel D, Koller D, Roth FP, Iakoucheva LM, Dunker AK, Bonneau R, et al. A protein domain-based interactome network for C. elegans early embryogenesis. Cell 2008, 134:534-545. 10.1016/j.cell.2008.07.009, 2596478, 18692475.
25. Finn RD, Tate J, Mistry J, Coggill PC, Sammut SJ, Hotz HR, Ceric G, Forslund K, Eddy SR, Sonnhammer EL, Bateman A. The Pfam protein families database. Nucleic Acids Res 2008, 36:D281-D288. 10.1093/nar/gkn226, 2238907, 18039703.
26. Romero P, Obradovic Z, Dunker AK. Natively disordered proteins: functions and predictions. Appl Bioinformatics 2004, 3:105-113. 10.2165/00822942-200403020-00005, 15693736.
27. Walhout AJ, Vidal M. High-throughput yeast two-hybrid assays for large-scale protein interaction mapping. Methods 2001, 24:297-306. 10.1006/meth.2001.1190, 11403578.
28. Vidalain PO, Boxem M, Ge H, Li S, Vidal M. Increasing specificity in high-throughput yeast two-hybrid experiments. Methods 2004, 32:363-370. 10.1016/j.ymeth.2003.10.001, 15003598.
29. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004, 101:6062-6067. 10.1073/pnas.0400782101, 395923, 15075390.
30. Depping R, Steinhoff A, Schindler SG, Friedrich B, Fagerlund R, Metzen E, Hartmann E, Kohler M. Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin a/b pathway. Biochim Biophys Acta 2008, 1783:394-404. 10.1016/j.bbamcr.2007.12.006, 18187047.
31. Chen M, Takano-Maruyama M, Pereira-Smith OM, Gaufo GO, Tominaga K. MRG15, a component of HAT and HDAC complexes, is essential for proliferation and differentiation of neural precursor cells. J Neurosci Res 2009, 87:1522-1531. 10.1002/jnr.21976, 2913448, 19115414.
32. Garcia SN, Kirtane BM, Podlutsky AJ, Pereira-Smith OM, Tominaga K. Mrg15 null and heterozygous mouse embryonic fibroblasts exhibit DNA-repair defects post exposure to gamma ionizing radiation. FEBS Lett 2007, 581:5275-5281. 10.1016/j.febslet.2007.10.017, 2132445, 17961556.
33. Tominaga K, Kirtane B, Jackson JG, Ikeno Y, Ikeda T, Hawks C, Smith JR, Matzuk MM, Pereira-Smith OM. MRG15 regulates embryonic development and cell proliferation. Mol Cell Biol 2005, 25:2924-2937. 10.1128/MCB.25.8.2924-2937.2005, 1069611, 15798182.
34. Pardo PS, Leung JK, Lucchesi JC, Pereira-Smith OM. MRG15, a novel chromodomain protein, is present in two distinct multiprotein complexes involved in transcriptional activation. J Biol Chem 2002, 277:50860-50866. 10.1074/jbc.M203839200, 12397079.
35. Stiernagle T. Maintenance of C. elegans. WormBook 2006, 1:1-11.
36. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
37. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009, 18:4442-4456. 10.1093/hmg/ddp372, 2782243, 19656774.
38. CIMBA. , http://www.srl.cam.ac.uk/consortia/cimba/eligibility/eligibility.html
39. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, Easton DF. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005, 29:1-11. 10.1002/gepi.20074, 15880399.
40. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59. 10.1038/ng879, 11967536.
41. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004, 337:635-645. 10.1016/j.jmb.2004.02.002, 15019783.
42. Lobley A, Swindells MB, Orengo CA, Jones DT. Inferring function using patterns of native disorder in proteins. PLoS Comput Biol 2007, 3:e162. 10.1371/journal.pcbi.0030162, 1950950, 17722973.
43. Pedrazzi G, Perrera C, Blaser H, Kuster P, Marra G, Davies SL, Ryu GH, Freire R, Hickson ID, Jiricny J, Stagljar I. Direct association of Bloom's syndrome gene product with the human mismatch repair protein MLH1. Nucleic Acids Res 2001, 29:4378-4386. 10.1093/nar/29.21.4378, 60193, 11691925.
44. Park CH, Sancar A. Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins. Proc Natl Acad Sci USA 1994, 91:5017-5021. 10.1073/pnas.91.11.5017, 43921, 8197175.
45. Meetei AR, Sechi S, Wallisch M, Yang D, Young MK, Joenje H, Hoatlin ME, Wang W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003, 23:3417-3426. 10.1128/MCB.23.10.3417-3426.2003, 164758, 12724401.
46. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005, 437:1173-1178. 10.1038/nature04209, 16189514.
47. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009, 138:389-403. 10.1016/j.cell.2009.04.042, 2716422, 19615732.
48. Moshkin YM, Kan TW, Goodfellow H, Bezstarosti K, Maeda RK, Pilyugin M, Karch F, Bray SJ, Demmers JA, Verrijzer CP. Histone chaperones ASF1 and NAP1 differentially modulate removal of active histone marks by LID-RPD3 complexes during NOTCH silencing. Mol Cell 2009, 35:782-793. 10.1016/j.molcel.2009.07.020, 19782028.
49. Collins SR, Miller KM, Maas NL, Roguev A, Fillingham J, Chu CS, Schuldiner M, Gebbia M, Recht J, Shales M, Ding H, Xu H, Han J, Ingvarsdottir K, Cheng B, Andrews B, Boone C, Berger SL, Hieter P, Zhang Z, Brown GW, Ingles CJ, Emili A, Allis CD, Toczyski DP, Weissman JS, Greenblatt JF, Krogan NJ. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810. 10.1038/nature05649, 17314980.
50. Temime-Smaali N, Guittat L, Wenner T, Bayart E, Douarre C, Gomez D, Giraud-Panis MJ, Londono-Vallejo A, Gilson E, Amor-Gueret M, Riou JF. Topoisomerase IIIα is required for normal proliferation and telomere stability in alternative lengthening of telomeres. Embo J 2008, 27:1513-1524. 2396391, 18418389.
51. Aoki K, Suzuki K, Sugano T, Tasaka T, Nakahara K, Kuge O, Omori A, Kasai M. A novel gene, translin, encodes a recombination hotspot binding protein associated with chromosomal translocations. Nat Genet 1995, 10:167-174. 10.1038/ng0695-167, 7663511.
52. Jacob E, Pucshansky L, Zeruya E, Baran N, Manor H. The human protein translin specifically binds single-stranded microsatellite repeats, d(GT)n, and G-strand telomeric repeats, d(TTAGGG)n: a study of the binding parameters. J Mol Biol 2004, 344:939-950. 10.1016/j.jmb.2004.09.095, 15544804.
53. Jaendling A, McFarlane RJ. Biological roles of translin and translin-associated factor-X: RNA metabolism comes to the fore. Biochem J 2010, 429:225-234. 10.1042/BJ20100273, 20578993.
54. Leteurtre F, Li X, Guardiola P, Le Roux G, Sergere JC, Richard P, Carosella ED, Gluckman E. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol 1999, 105:883-893. 10.1046/j.1365-2141.1999.01445.x, 10554797.
55. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood 1998, 91:3582-3592.
56. Callén E, Samper E, Ramírez MJ, Creus A, Marcos R, Ortega JJ, Olivé T, Badell I, Blasco MA, Surrallés J. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. Hum Mol Genet 2002, 11:439-444. 10.1093/hmg/11.4.439, 11854176.
57. Fan Q, Zhang F, Barrett B, Ren K, Andreassen PR. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res 2009, 37:1740-1754. 10.1093/nar/gkn995, 2665210, 19129235.
58. Franco S, van de Vrugt HJ, Fernández P, Aracil M, Arwert F, Blasco MA. Telomere dynamics in Fancg-deficient mouse and human cells. Blood 2004, 104:3927-3935. 10.1182/blood-2003-10-3626, 15319283.
59. Rhee DB, Wang Y, Mizesko M, Zhou F, Haneline L, Liu Y. FANCC suppresses short telomere-initiated telomere sister chromatid exchange. Hum Mol Genet 2010, 19:879-887. 10.1093/hmg/ddp556, 2816614, 20022886.
60. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006, 22:719-729. 10.1016/j.molcel.2006.05.022, 16793542.
61. Martin JS, Winkelmann N, Petalcorin MI, McIlwraith MJ, Boulton SJ. RAD-51-dependent and -independent roles of a Caenorhabditis elegans BRCA2-related protein during DNA double-strand break repair. Mol Cell Biol 2005, 25:3127-3139. 10.1128/MCB.25.8.3127-3139.2005, 1069622, 15798199.
62. Ko E, Lee J, Lee H. Essential role of brc-2 in chromosome integrity of germ cells in C. elegans. Mol Cells 2008, 26:590-594.
63. Fujita M, Takasaki T, Nakajima N, Kawano T, Shimura Y, Sakamoto H. MRG-1, a mortality factor-related chromodomain protein, is required maternally for primordial germ cells to initiate mitotic proliferation in C. elegans. Mech Dev 2002, 114:61-69. 10.1016/S0925-4773(02)00058-8, 12175490.
64. Takasaki T, Liu Z, Habara Y, Nishiwaki K, Nakayama J, Inoue K, Sakamoto H, Strome S. MRG-1, an autosome-associated protein, silences X-linked genes and protects germline immortality in Caenorhabditis elegans. Development 2007, 134:757-767. 10.1242/dev.02771, 2435364, 17215300.
65. Rio Frio T, Haanpaa M, Pouchet C, Pylkas K, Vuorela M, Tischkowitz M, Winqvist R, Foulkes WD. Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families. J Hum Genet 2010, 55:842-843. 10.1038/jhg.2010.112, 20844547.
66. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217. 10.1126/science.1171202, 2684332, 19264984.
67. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874. 10.1038/ng2075, 17529973.
68. Jorgenson TC, Williams BR, Wendland A, Bilger A, Sandgren EP, Drinkwater NR. Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer. Cancer Res 2010, 70:8398-8406. 10.1158/0008-5472.CAN-09-3980, 20959479.
69. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82:937-948. 10.1016/j.ajhg.2008.02.008, 2427217, 18355772.